Literature DB >> 25193155

Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer.

Arash O Naghavi1, Tobin J Strom, Kevin Nethers, Alex A Cruz, Nicholas B Figura, Kushagra Shrinath, Binglin Yue, Jongphil Kim, Matthew C Biagioli, Daniel C Fernandez, Randy V Heysek, Richard B Wilder.   

Abstract

BACKGROUND: The objectives are to determine predictors of a prostate-specific antigen (PSA) bounce, whether a PSA bounce after radiotherapy for prostate cancer is associated with biochemical disease-free survival (bDFS), and the time course to a PSA bounce versus a biochemical failure post-irradiation.
METHODS: Between July 2000 and December 2012, 691 prostate cancer patients without regional or distant metastases were treated with external beam radiation therapy and/or brachytherapy, and had at least 12 months of follow-up. A PSA bounce was defined as a temporary PSA increase of ≥ 0.4 ng/mL. bDFS was defined according to the nadir + 2 definition.
RESULTS: The median follow-up was 42 months. The median time to first PSA bounce was 17 months (95% confidence interval 15-18 months). In contrast, the median time to biochemical failure was 41 months (95% confidence interval 28-53 months). Two hundred and twenty-six of 691 (33%) patients had at least one PSA bounce with a median magnitude of 1.0 ng/mL (range 0.4-17.0). A Gleason score of 6 (p < 0.0001) predicted a PSA bounce on multivariate analysis. Patients with a PSA bounce experienced improved bDFS on multivariate analysis (p = 0.002).
CONCLUSIONS: Patients with a Gleason score of 6 were more likely to experience a PSA bounce which was associated with improved bDFS. A PSA bounce occurred sooner after radiotherapy than a biochemical failure. The authors recommend against performing prostate biopsies within 24-30 months of radiotherapy since an elevated PSA may simply represent a benign PSA bounce.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25193155     DOI: 10.1007/s10147-014-0745-8

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  28 in total

1.  Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.

Authors:  Eric M Horwitz; Lawrence B Levy; Howard D Thames; Patrick A Kupelian; Alvaro A Martinez; Jeffrey M Michalski; Thomas M Pisansky; Howard M Sandler; William U Shipley; Michael J Zelefsky; Anthony L Zietman; Deborah A Kuban
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

2.  Volumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study.

Authors:  R Shaffer; W J Morris; V Moiseenko; M Welsh; C Crumley; S Nakano; M Schmuland; T Pickles; K Otto
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-03-05       Impact factor: 4.126

3.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.

Authors:  Brian J Davis; Eric M Horwitz; W Robert Lee; Juanita M Crook; Richard G Stock; Gregory S Merrick; Wayne M Butler; Peter D Grimm; Nelson N Stone; Louis Potters; Anthony L Zietman; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2012 Jan-Feb       Impact factor: 2.362

4.  Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer.

Authors:  W Cavanagh; J C Blasko; P D Grimm; J E Sylvester
Journal:  Semin Urol Oncol       Date:  2000-05

5.  Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.

Authors:  F A Critz; W H Williams; J B Benton; A K Levinson; C T Holladay; D A Holladay
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

6.  Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce.

Authors:  Prajnan Das; Ming-H Chen; Kristin Valentine; Lynn Lopes; Robert A Cormack; Andrew A Renshaw; Clare M Tempany; Sanjaya Kumar; Anthony V D'Amico
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

7.  Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.

Authors:  Tom Pickles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-10       Impact factor: 7.038

8.  Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?

Authors:  Katherine O Castle; Karen E Hoffman; Lawrence B Levy; Andrew K Lee; Seungtaek Choi; Quynh N Nguyen; Steven J Frank; Thomas J Pugh; Sean E McGuire; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-24       Impact factor: 7.038

9.  Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population.

Authors:  K Komatsu; N Wehner; A F Prestigiacomo; Z Chen; T A Stamey
Journal:  Urology       Date:  1996-03       Impact factor: 2.649

10.  Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.

Authors:  A F Prestigiacomo; T A Stamey
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

View more
  3 in total

Review 1.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

2.  Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy.

Authors:  Michael Rowe; Ellis Adamson; John McGrane
Journal:  Int Cancer Conf J       Date:  2020-06-27

3.  Prostate-Specific Antigen Bounce after 125I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer.

Authors:  Tae Hyung Kim; Jason Joon Bock Lee; Jaeho Cho
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.